Keywords: EMA. CHMP, Opinions, Forxiga, Jakavi, Rienso, Flutiform, Glybera, Amsterdam Molecular, AstrZeneca, Incyte, Novartis, Takeda, AMAG Pharma, SkyePharma
Positive opinions from CHMP for Forxiga, Jakavi, Rienso and Flutiform but not Glybera
Article | 22 April 2012
There was a batch of good news for several drugmakers coming out of the discussion meetings last week of the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
